If you see this message, your browser is not running JavaScript.
Turn on JavaScript support and enjoy the site.

UWAGA!!! Jeśli widzisz tą wiadomość oznacza to, że Twoja przeglądarka ma wyłaczoną obsługę JavaScript.
Obsługa JavaScript musi być włączona aby dalej korzystać ze strony.
Benign prostatic hyperplasia (BPH)
Non-malignant enlargement of the prostate, called BPH (Benign Prostatic Hyperplasia) is a consequence of excessive prostatic growth and is characterized by troublesome lower urinary tract symptoms, deteriorating the quality of life, both during the day and at night.
More information about the disease can be found in the section: What is benign prostatic hyperplasia?

It is one of the most common complaints in men after age of 50.

Effective treatment of BPH is based on elimination of the causes of symptoms burdensome for the patients, mainly associated with urine excretion. The choice of an appropriate treatment method depends on the intensity of symptoms and complaints associated with the lower urinary tract, the patient’s age and general condition, and coincident diseases. The decision concerning the choice of treatment is made by the doctor, who takes into consideration the patient’s individual needs and preferences.

Depending on the severity of symptoms treatment of benign prostatic hyperplasia involves: (according to Guidelines of European Association of Urology-EAU) www.uroweb.org
  • medical consultation (prevention, diet, hygiene)
  • pharmaceutical therapy - for patients with moderate symptoms, without complications such as urine retention, urolithiasis, hematuria.
Pharmacutical therapy alleviates the complaints associated with lower urinary tract symptoms increasing overall quality of life.

Following therapies are used in treatment of BPH:

  • 5 α-reductase inhibitors – inhibit the enlargement, or even reduce the size, of the prostate, provided that the treatment is continued for many months, or even for many years.
  • α 1-adrenergic receptor blockers – act by reducing smooth muscle tone, alleviating the symptoms of irritation.
  • agents of herbal origin – with anti-inflammatory, edema-reducing and anti-androgenic effect.
     Surgical treatment
  • surgical treatment – in patients with complications such as: urine retention requiring catheterization of the bladder, urolithiasis, vesical diverticulosis, chronic, recurrent or bacterial infections of the urinary tract, hematuria, bilateral hydronephrosis or renal failure.
Benign prostatic hyperplasia is a very common complaint among men above fifty years of age.
Before use, read the leaflet containing indications, contraindications, data and information concerning adverse effects and dosage, as well as information concerning the use of the medicinal product, or consult a doctor or a pharmacist, because each drug used inappropriately poses a risk for your life and health.
PROSTAMOL UNO: 1 capsule contains 320 mg of Sabalis serrulatae extractum; Indications: relieves complaints related to prostate gland hypertrophy associated with urination, such as, e.g., poor stream of urine, urgent urination, pollakiuria, frequent urination at night. Contrindications: allergy (hypersensitivity) to the active ingredient of the medicine or to any of its excipients; Marketing Authorisation Holder: Berlin Chemie AG, Germany Further information can be obtained at: Berlin-Chemie/Menarini Polska Sp. z o.o, ul. Cybernetyki 7b, 02-677 Warszawa, tel: (22) 566 21 00, fax: (22) 566 21 01